1.01 | Governance, leadership and culture: the governing body endorses the clinical governance and risk frameworks, puts patient safety and appropriate test use ahead in business and cont | 1 |
1.02 | Designated person: the governing body places delivery of pathology services under the direction and control of an Ahpra-registered medical practitioner residing in Australia with t | 2 |
1.03 | Delegations: operate an authorisation process that delegates responsibility for aspects of the practice only to workforce members with the qualifications and skills for the task wh | 2 |
1.04 | Legislation and standards: comply with applicable Commonwealth, state and territory legislation and regulations, the relevant NPAAC standards and, where no NPAAC standard covers a | 1 |
1.05 | Contracted services: where the practice subcontracts or coordinates pathology services for other organisations, ensure subcontractors are accredited to the relevant NPAAC standards | 1 |
1.06 | Referral laboratories: ensure Australian referral laboratories are accredited to the relevant NPAAC standards and ISO 15189, prefer accredited international laboratories, communica | 1 |
1.07 | Environmental sustainability: use the governance systems to implement best practice strategies that reduce the practice's environmental impact | 1 |
1.08 | Information governance: implement interoperable health information systems conformant with national digital health standards and legislation, monitor data quality, keep laboratory | 1 |
1.09 | Artificial intelligence governance: implement an AI management system consistent with relevant international standards such as ISO/IEC 42001 | 1 |
10.01 | Analytical and clinical performance requirements: document for every area of testing the analytical and clinical performance requirements using key indicators for quantitative anal | 1 |
10.02 | Analytical and clinical performance: ensure analytical performance meets the assay's clinical application, support morphological and interpretive diagnostic performance through pee | 1 |
10.03 | Measurement uncertainty process: for quantitative assays define the measurand, indicate the laboratory's confidence in each measurement, provide information for interpreting result | 1 |
10.04 | Measurement uncertainty use: match the effort spent on uncertainty to the clinical quality requirements, set routine performance goals and reduce uncertainty sources when goals are | 1 |
10.05 | Quality control process: the designated person oversees quality control, every assay has a documented quality control process assessing performance, the process specifies the crite | 1 |
10.06 | Frequency of quality control testing: test control samples at a frequency based on the stability and robustness of the method and the risk of patient harm, and additionally when cr | 1 |
10.07 | Test procedures: align with best practice guidelines, follow the manufacturer's instructions or the practice's validated and authorised variation, maintain specimen integrity throu | 1 |
10.08 | Test results: ensure the workforce determining results are competent, work in optimal conditions with appropriate equipment for interpretation, have evidence-based reference interv | 1 |
10.09 | Disposal of biological material: hold a waste management policy and comply with jurisdictional regulations on the disposal of biological material from pathology testing | 0 |
10.10 | External quality assurance programs: participate in EQA for the preanalytical, analytical and postanalytical phases of every test or test group with an available program, assess pr | 1 |
10.11 | Morphological external quality assurance: ensure every workforce member involved in morphological diagnosis takes part in at least one relevant EQA program a year, retain individua | 1 |
10.12 | Internal quality assurance: where no suitable EQA exists, use alternative internal quality assurance for the preanalytical, analytical and postanalytical phases, addressing high-ri | 1 |
11.01 | Contracted PoCT services: where the practice coordinates point of care testing for a health service, hold an agreement that specifies each party's roles and responsibilities | 0 |
11.02 | PoCT roles and responsibilities: ensure the workforce performing point of care testing are skilled, competent and within scope, can perform, interpret, monitor and produce reliable | 1 |
11.03 | PoCT training: scale training to device complexity, test volume, operator frequency and quality assessment findings; have a qualified person deliver defined training covering at mi | 1 |
11.04 | PoCT performance management: review the performance of workforce members undertaking point of care testing to ensure competence, and identify their training, development and superv | 0 |
11.05 | Interprofessional collaboration: when coordinating point of care testing for health services, provide opportunities for collaboration between the practice's workforce and the clini | 0 |
11.06 | PoCT procedures: in addition to the practice's test procedures, ensure PoCT procedures include traceability of samples to the original specimen, patient and device, include referen | 1 |
11.07 | PoCT test results: ensure results and related information from point of care devices are included in the patient's healthcare record, automatically where possible | 1 |
2.01 | Policies and procedures: establish policies and processes for every laboratory and service, make them readily available to the workforce and support their use, monitor and improve | 1 |
2.02 | Risk management: establish and operate a risk management system that identifies, reviews and mitigates risks, records safety and quality risks in the risk plan, uses clinical and o | 1 |
2.03 | Ongoing service provision: maintain business continuity plans, reviewed regularly and improved, that keep pathology services running through disruptions, emergencies and disasters | 0 |
2.04 | Adaptable and resilient systems: manage software updates and system changes through a change control process, validate and test changes affecting regulated software before clinical | 1 |
2.05 | Interoperable information systems: use national healthcare identifiers for patients, organisations and providers, apply standard information structures and national terminologies i | 1 |
2.06 | Appropriate care: identify, assess and implement contemporary evidence-based pathology services and technologies that improve clinical care, and identify and reduce pathology servi | 1 |
2.07 | Quality management systems: collect and interpret safety and quality data on specimen collection, integrity, traceability and testing, equipment testing, result interpretation and | 1 |
2.08 | Incident management: support the workforce to recognise and report incidents and involve them in review, let consumers and requesters raise concerns, nominate investigators with ri | 1 |
2.09 | Open disclosure: use an open disclosure process consistent with the Australian Open Disclosure Framework and monitor and improve its use and effectiveness | 1 |
2.10 | Feedback and complaints management: document feedback and complaints from requesters, patients, families and carers, inform the designated person, escalate and correct where commun | 1 |
3.01 | Supervision requirements: ensure the workforce delegated to supervise pathology tests understand their responsibilities and are trained for them, support requesters with enquiries, | 1 |
3.02 | Supervision framework: document a supervision framework that delegates supervision of every pathology test to supervising medical practitioners within their scope of practice, ensu | 2 |
3.03 | Workforce and supervision risks: record and rate supervision risks from vacancies and extended leave in the risk system, rate skills and supervisory gaps from vacancy or extended l | 1 |
3.04 | Mitigating supervision risks: actively recruit to vacancies and give supervising medical practitioners, clinical scientists and scientists access to training and experience that ma | 1 |
4.01 | GX laboratory designated person: a full-time pathologist appointee who supervises only within scope, delegates supervision of tests outside their scope to pathologists with the rel | 2 |
4.02 | GX laboratory pathologist and clinical scientist supervision: at least one full-time equivalent pathologist with the relevant scope who is onsite in a laboratory 80 percent of the | 0 |
4.03 | GY and B laboratories are associated with the GX laboratory in the same pathology network, and the GX designated person holds responsibility for their clinical governance | 0 |
4.04 | GY and B laboratories operate under the network supervision framework the designated person developed, with onsite supervising pathologists of appropriate scope providing supervisi | 1 |
4.05 | GY and B laboratories: undertake a documented, ongoing risk assessment of the adequacy of onsite supervision covering test volume, complexity and acuity, workforce composition and | 1 |
4.06 | GX, GY and B clinical governance: run a common clinical governance system across GX, GY and B laboratories | 0 |
4.07 | GY and B laboratories receive effective virtual supervision through at least monthly meetings with time for safety, quality and operational performance, annual visits by skilled an | 0 |
4.08 | S laboratory: perform a limited range of tests for a target population related to the designated person's qualifications, skills and scope, apply for GX status if wider testing is | 1 |
4.09 | Complex genomic testing in S laboratories: where an S laboratory performs complex genomic testing, both a genetic pathologist and a clinical scientist with relevant scope supervise | 0 |
4.10 | SB laboratories are associated with an S laboratory in the same pathology network | 0 |
4.11 | Each SB laboratory has full-time supervision and clinical governance from an S laboratory designated person, a supervision framework that person developed, supervising specialist m | 0 |
4.12 | S and SB clinical governance: run a common clinical governance system across S and SB laboratories, give SB laboratories effective virtual supervision through at least monthly meet | 1 |
4.13 | M laboratory: perform a limited range of tests only for patients of the associated medical practice, consistent with the designated person's qualifications, skills and defined scop | 0 |
4.14 | M laboratory test scope: provide tests using IVD medical devices included in the ARTG or otherwise permitted under the therapeutic goods framework, from haematology (excluding immu | 0 |
4.15 | M laboratory designated person: a medical practitioner competent to provide the tests performed, who has completed a training program in the operation, monitoring and use of the in | 2 |
4.16 | M laboratory supervision framework: delegations clearly set out who holds authority for pathology tests during operational hours | 0 |
4.17 | M laboratory competence: the designated person assesses the skills and competence of the workforce performing pathology tests every year | 0 |
5.01 | Pathology workforce roles and responsibilities: confirm qualifications, knowledge, experience, skills and recency of practice, define functions and responsibilities and support the | 1 |
5.02 | Training to improve the quality of patient care: orient and train the workforce in their safety and quality roles on commencement and when those responsibilities change, provide ac | 1 |
5.03 | Evidence-based care: give the workforce ready access to professional and best practice guidelines, decision-support tools and resources relevant to their practice, and support thei | 1 |
6.01 | Healthcare rights: deliver person-centred care aligned to a charter of rights consistent with the Australian Charter of Healthcare Rights, support the workforce to apply its princi | 1 |
6.02 | Informed consent: ensure consent processes comply with legislation, enable patients to consent to specimen collection and, where required, to testing, give transparent financial in | 2 |
6.03 | Decision-making: at collection centres identify patients who need support to make decisions, give them access to that support and involve supporters and substitute decision-makers | 1 |
6.04 | Accessing specimen collection services: make information available to patients and carers on the collection services offered, contact details, locations, opening hours, bookings an | 1 |
6.05 | People with diverse care needs: provide a safe environment and deliver person-centred, culturally safe care when collecting specimens and communicating results | 1 |
7.01 | Supporting requesters: advise on available services, request requirements including the clinical information needed, appropriateness, limitations, prerequisites and preparation, co | 1 |
7.02 | Patient identification and service matching: define and approve at least three patient identifiers for the record and primary specimen label, include national health identifiers wh | 1 |
7.03 | Communicating results: use a results system that supports interoperability through SPIA-aligned terminology and structures, addresses report structure and content, delivers accurat | 1 |
7.04 | Reporting critical results: use processes that promptly recognise critical results (preferably automated), interpret and report them in a timely manner across all operational perio | 2 |
7.05 | Healthcare records: collect, store and share patient information and pathology records in line with national and jurisdictional legislation including sharing-by-default requirement | 1 |
7.06 | Notifiable diseases: document and report notifiable diseases to the relevant authorities and disease registries in accordance with jurisdictional requirements | 0 |
8.01 | Medical device implementation and replacement: ensure devices are on the ARTG or, if developed in-house, validated to ISO 15189 and compliant with NPAAC and regulatory requirements | 1 |
8.02 | Medical device use: use devices for their intended purpose per the manufacturer's instructions for use, classify commercial IVDs used outside their intended purpose (such as unspec | 1 |
8.03 | Medical device maintenance: keep a current and complete device inventory, store devices per the manufacturer's instructions, use in-date reagents and consumables per the instructio | 1 |
8.04 | In-house IVD medical devices: validate clinical and analytical performance, comply with TGA requirements for in-house IVDs, assess against the NPAAC in-house IVD requirements, demo | 1 |
8.05 | Adverse medical device events: report adverse events involving commercial and in-house IVD medical devices to the TGA within the specified timeframes, in the required format and in | 0 |
8.06 | IVD software and AI governance and implementation: ensure commercial IVD software is on the ARTG and in-house IVD software including diagnostic AI is managed as an in-house IVD und | 1 |
8.07 | IVD software and AI clinical use and oversight: use IVD software and AI only for their intended purpose and with evidence of clinical benefit or improved accuracy, efficiency or de | 1 |
9.01 | Specimen collection environment: comply with regulations and jurisdictional requirements, design, maintain and equip facilities to support safe care, provide fit-for-purpose and we | 1 |
9.02 | Infection prevention and control in collection centres: keep a clean, safe and hygienic environment consistent with the national infection control guidelines and state or territory | 1 |
9.03 | Recognising acute deterioration and escalating care: implement processes to respond promptly when a patient's physical or cognitive state deteriorates acutely, have referral pathwa | 1 |
9.04 | Request assessment: perform services only on a documented request naming the patient, requesting practitioner and services, assess Medicare-funded requests for compliance with the | 1 |
9.05 | Specimen collection processes: describe each service, its purpose, the standard collection procedure, temperature-controlled storage needs and maximum storage time; keep processes | 1 |
9.06 | Optimising specimen collection: keep consumables available, in date and easy to find and use, have the collection workforce maintain specimen integrity through correct preparation, | 1 |
9.07 | Specimen storage: provide dedicated, suitable and secure storage at the required temperature, follow and document safety, stability and security requirements for specimens retained | 1 |
9.08 | High acuity settings and critical requests: ensure high acuity settings know who collects and transports specimens, use evidence-based approaches so testing occurs within the clini | 1 |
Background | Background: the Commission administers the National Pathology Accreditation Scheme, NPAAC formulates the standards, NATA assesses conformity, and the Approval Principles under the | 0 |
Glossary | Glossary: the defined terms the actions rely on, including designated person, clinical scientist, supervising medical practitioner, critical results, high acuity setting, critical | 0 |
Introduction | Introduction and application: a nationally consistent framework that replaces seven NPAAC requirements, read with the Approval Principles, binding on Medicare-funded pathology prac | 0 |